45 results about "Polyoma virus" patented technology

A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, alone or in combination with low levels of light or other drugs, to selectively inactivate or inhibit hepatitis infection, has been developed. Clinical trial results demonstrate efficacy in a human clinical trial for treatment of hepatitis C by oral administration of methylene blue immediate release formulation, in a dosage of 65 mg twice daily, over a period of at least 100 days. A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, along or in combination with low levels of light or other drugs, to prevent or decrease reactivation of viruses, is also described. The preferred class of patient is infected with, or has been exposed to, viruses such as Herpes simplex virus type 1 & 2, Varicella zoster virus, Epstein-Barr virus, Cytomegalovirus, and Herpes virus type 6 & 7, Adenovirus, and Human polyoma viruses, e.g. JC virus and BK virus. In one embodiment the thiazine dye is administered to a patient experiencing symptoms or disease caused by reactivation of a virus. In a preferred embodiment the thiazine dye is administered to a patient at risk for or experiencing symptoms or disease caused by reactivation of a virus, prior to or during immunosuppression or chemotherapy.

RNA interference using small interfering RNAs which are specific for mRNA produced from the JCV agnoprotein and large T antigen genes inhibits expression of these and other primate polyomavirus genes. Primate polyomavirus infection, and diseases which are associated with primate polyomavirus infection, can be treated by administering the small interfering RNAs.

The present invention relates to PMEA lipid conjugates and to methods of using the conjugates to treat diseases caused by viruses such as herpes, cytomegalovirus, varicella, paramyxovirus, polyoma virus, and human papillomavirus. Methods for making the PMEA lipid conjugates are also provided.

The invention provides a multiplex PCR primer set, a kit and a method for simultaneous detection of EHV (Eel herpes virus), JEECV (Japanese eel endothelial cells-infecting virus) and AmPV (Anguilla marmorata polyoma-like virus). According to obtained nucleic acid sequences, specific primers for amplification of EHV, JEECV and AmPV are designed to avoid formation of stable primer dimmers between primers, specificity of primer amplified sequences is analyzed to obtain the primer set that is composed of 6 nucleic acid sequences including SEQ ID NO:1-6 and has high amplification sensitivity and specificity on EHV, JEECV and AmPV simultaneously. The multiplex PCR primer set, kit and method provided by the invention can simultaneously detect and identify EHV, JEECV and AmPV in one PCR reaction system, have the advantages of simple operation and strong specificity, etc., and can directly determine the result according to different amplification lengths, thus being more efficient and practical.

The invention discloses application of diacerein in preparation of antiviral drugs and treatment of virus infection, and belongs to new application of diacerein. The experimental results prove that diacerein can be used for effectively inhibiting hepatophilic DNA viruses, retroviruses, enteroviruses, orthomyxoviruses, fibroviruses, reoviruses, arenavirus, hepatitis E viruses, astroviruses, circoviruses, coronaviruses, parvoviruses, adenoviruses, polyomaviruses, herpes viruses, poxviruses, human papillomaviruses, paramyxoviruses, flaviviruses, herpes viruses, alphaviruses and rhabdoviruses.

The invention relates to VLP derived from human polyoma virus loaded with a drug (cargo) as a drug delivery system for transporting said drug into the CNS, in particular of living humans.

The invention relates to methods for the production of a recombinant protein in a mammalian cell and methods to enhance the production of recombinant proteins in mammalian cells. More in particular, the invention provides a cell for the production of a recombinant protein of interest wherein said cell is permissive to a polyomavirus and wherein said cell comprises the genetic elements A and B wherein A encodes a polyomaviral large T antigen or a functional equivalent thereof and B comprises a gene encoding a protein of interest under the functional control of a polyomaviral origin of replication or a functional equivalent thereof, wherein said cell lacks the capability to express a polyomaviral small T antigen or a functional equivalent thereof as well as the capability to express a polyomavirus capsid protein.

The present invention provides a method for restoring immune tolerance in vivo. The invention relates to the use of a recombinant gene encoding auto-antigens or parts thereof for restoring immune tolerance to the auto-antigens in vivo, under transcriptional control of polyomaviral early and late promoters. In a preferred embodiment, the invention relates to the use of recombinant polyomaviral gene delivery vector particles, such as simian virus 40 (SV40) viral vector particles encoding one or multiple auto-antigens or parts thereof under transcriptional control of the SV40 early and late promoter, for restoring immune tolerance to the auto-antigens in vivo. The invention also relates to compositions comprising recombinant genes or polyomaviral vectors and uses thereof as treatment for degenerative or dystrophic diseases.

The invention discloses a method for detecting JC polyoma virus through real-time fluorescent quantitative PCR (Polymerase Chain Reaction), provides a group of forward primers, reverse primers and probes for detecting JC virus in a biological product through real-time fluorescent quantitative PCR, and provides a PCR program for carrying out fluorescent quantitative PCR detection by utilizing the forward and reverse primers and the probes. The detection method provided by the invention can be used for detecting all JC viruses of different genotypes, is good in specificity, high in sensitivity and high in variant coverage, and compared with common virus cell culture detection, the detection time is greatly shortened, the labor and material cost is saved, and the detection method is suitable for complex detection of large-batch production of biological products.

The invention discloses a marker for predicting the range and depth of kidney infection of polyoma virus and application thereof. Experiments verify that the combined detection of 58K Golgi protein and polyoma virus specific antigen has important application value in predicting the range and depth of transplanted kidney infection and prognosis of kidney transplantation patients, and is helpful forrisk stratification of infection and adoption of appropriate treatment strategies. The sample adopted by the detection strategy of the invention is urine sediment cells, which can be realized by non-invasive means, and the operation is simple, and most of the processes can be automated and almost can be carried out in each transplantation center.